Well, that’s concerning.
I’m an elderly person who’s been on bisphosphates on and off since 2017. I have no original teeth. Rather, crowns, bridges, and implants. Had lots of dental work done over that period. So far, at least, no indication that bispho’s had any negative effect. N of 1 of course. YMMV.
I asked gpt to chase down the studies that support this assertion. Results follow. If the studies behind this claim aren’t considered in the ai search below, please share.
As always, if you’re unlucky enough to be the ‘1 in 2000’ to experience a rare side (severe) effect, you don’t get a do-over. So a good reason to be cautious.
The claim in that post is considerably stronger than the evidence supports. I can find solid evidence that bisphosphonates can produce long-lasting suppression of bone remodeling in alveolar bone, and that drug remains associated with the skeleton for years. I cannot find evidence showing that an osteoporosis-dose course causes the bone around the teeth to become permanently damaged or permanently inferior for dental work.
The distinction matters: persistent pharmacologic effect ≠ permanent structural damage.
Where the claim probably comes from
| Evidence |
What it actually shows |
| Very long skeletal retention |
Alendronate binds hydroxyapatite and has an estimated terminal skeletal half-life of >10 years. But that figure is a pharmacokinetic estimate; a later pharmacology review cautions that the often-quoted 10-year number is extrapolated and shouldn’t be interpreted too literally. Stored drug is largely inactive until the bone surface is resorbed. (dailymed.nlm.nih.gov) |
| Alveolar remodeling suppression |
In beagles given clinically relevant alendronate for 3 years, alveolar mandibular turnover was about 75% lower, and focal microscopic necrotic areas occurred in 25–33% of treated animals versus none of the controls. Importantly, none developed clinically exposed jaw bone. This is probably one of the strongest experiments supporting concern specifically about alveolar bone. (pmc.ncbi.nlm.nih.gov) |
| Abnormal human jaw tissue in MRONJ |
Biopsies from people who had actually developed bisphosphonate-related ONJ show abnormal remodeling, thicker trabeculae, fewer Haversian canals, osteocyte loss, etc. But these are selected diseased patients, often receiving high oncology doses, so they cannot establish that ordinary bisphosphonate users have the same pathology. (pubmed.ncbi.nlm.nih.gov) |
| Orthodontic effects |
Human case reports and small cohorts show slower tooth movement and sometimes sclerotic alveolar changes. A 2026 umbrella review says the effect on orthodontic tooth movement is consistent, but human evidence remains sparse and weak. (link.springer.com) |
The beagle study is particularly interesting because the alveolar portion of the jaw normally remodels much faster than non-alveolar mandibular bone. That provides a plausible mechanism for why the jaw is unusually vulnerable to potent antiresorptive therapy. But it still does not establish irreversible damage. (pmc.ncbi.nlm.nih.gov)
Human evidence is much more reassuring
There are several studies that actively cut against the “your dental bone is compromised forever” interpretation.
A randomized trial of 335 people with periodontal disease treated for two years with weekly alendronate found no excess alveolar bone loss or ONJ; among subjects with low mandibular BMD, alendronate actually reduced alveolar bone loss. (pubmed.ncbi.nlm.nih.gov)
A radiographic study of women treated with bisphosphonates for an average of roughly 4–5 years found no significant alteration of alveolar or basal jaw trabecular structure compared with untreated women. (pubmed.ncbi.nlm.nih.gov)
More directly relevant to dental surgery, a prospective study of women with osteoporosis taking alendronate or yearly zoledronic acid found that tooth-extraction sockets and overlying mucosa healed successfully; by 90 days all patients had mucosal healing, without requiring discontinuation of bisphosphonate treatment. (pubmed.ncbi.nlm.nih.gov) Another prospective study of 132 oral-bisphosphonate users did find slower socket healing after >5 years of treatment, but no cases of ONJ occurred. (pubmed.ncbi.nlm.nih.gov)
And the major randomized zoledronic-acid osteoporosis trial is especially useful here: 7,714 women, zoledronic acid 5 mg yearly versus placebo for three years. There was one potential ONJ case in the zoledronic-acid group and one in the placebo group; both resolved. (pubmed.ncbi.nlm.nih.gov)
What about future implants?
This is probably the most important implication of the post.
The 2025 International ONJ Taskforce systematically reviewed implant outcomes in osteoporosis patients receiving antiresorptives. Their conclusion was that current evidence does not show increased dental-implant failure, and they suggest that antiresorptive treatment does not have to be stopped before an implant. They explicitly say implants can generally be placed in osteoporosis patients receiving bisphosphonates, although the evidence quality for implant outcomes is low. (pubmed.ncbi.nlm.nih.gov)
There is nevertheless a small MRONJ signal. The accompanying 2025 meta-analysis found a pooled post-implant MRONJ rate of about 0.5% among antiresorptive-treated osteoporosis patients; one adjusted cohort suggested bisphosphonate exposure added about 3 MRONJ cases per 1,000 patients. Implant failure itself was not increased in the primary patient-level analysis. (pubmed.ncbi.nlm.nih.gov)
Another 2025 meta-analysis illustrates how uncertain the evidence remains: it found an implant-level failure RR of 1.74, but no patient-level increase (RR 1.01), no significant increase in marginal bone loss, and rated the evidence very low certainty. (pubmed.ncbi.nlm.nih.gov)
The “permanent” part does not hold up
There is excellent evidence that effects persist after treatment stops. In FLEX, after five years of alendronate followed by five years off treatment, bone-turnover markers gradually rose toward pretreatment levels. (pubmed.ncbi.nlm.nih.gov) With zoledronic acid, after three annual doses, measurable antiresorptive effects persisted for another three years, but BMD began declining and PINP rose—again demonstrating an offset of effect, rather than permanent suppression. (pmc.ncbi.nlm.nih.gov)
So I would rewrite the post’s assertion this way:
Bisphosphonates become incorporated into bone and can influence remodeling for years after treatment. Because alveolar bone has unusually high turnover, dental extraction and implant surgery carry a small persistent MRONJ risk, particularly with prolonged treatment and high oncology doses. There is no evidence that osteoporosis-dose bisphosphonates permanently render alveolar bone unhealthy or permanently compromise a patient’s ability to receive dental implants.
That’s substantially different from “you are stuck for life.”
For osteoporosis-dose zoledronic acid specifically, the evidence is substantially more reassuring than the post implies. The very alarming jaw literature is disproportionately derived from cancer patients receiving much larger and more frequent IV doses. AAOMS currently estimates MRONJ risk from bisphosphonates used for osteoporosis at roughly 0.02–0.04% overall, while still acknowledging that invasive dental procedures and longer exposure increase it. (aaoms.org)
Confidence: high that the “permanently altered and compromised for life” statement is not supported by the available human evidence. The more defensible claim is long-lived alteration of remodeling with a small, nonzero dental-surgical risk.
If useful, I can next dig specifically into zoledronic acid/Reclast and dental implants after 1, 2, or 3 annual 5-mg infusions; that would narrow this considerably to the exposure pattern most relevant to osteoporosis treatment.